Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck

Review decision - June 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 63 KB)

TA145 Head and neck cancer - cetuximab: review proposal - April 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 42 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 91 KB)

Head and neck cancer - cetuximab: appeal information

Appeal statement information

Head and neck cancer - cetuximab: Appeal documents

Merck Serono

Appeals received

Appeals received (PDF 75 KB)

Initial scrutiny letter

Initial scrutiny letter (PDF 31 KB)

Mouth Cancer Foundation

Appeals received

Appeals received (PDF 19 KB)

Initial scrutiny letter

Initial scrutiny letter (PDF 30 KB)

Royal College of Radiologists

Appeals received

Appeals received (PDF 49 KB)

Initial scrutiny letter

Initial scrutiny letter (PDF 30 KB)

Head and neck cancer - cetuximab: Result of Appeal

Head and neck cancer - cetuximab: final appraisal determination information

Head and neck cancer - cetuximab: final appraisal determination

Head and neck cancer - cetuximab: final appraisal determination (PDF 85 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 44 KB)

Consultee and commentator comments on the ACD

British Association of Head and Neck Oncologists

British Association of Head and Neck Oncologists (PDF 13 KB)

Welsh Association of Head and Neck Oncologists

Welsh Association of Head and Neck Oncologists (PDF 12 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 39 KB)

Royal College of Nursing

Royal College of Nursing (PDF 19 KB)

National Association of Laryngectomee Clubs

National Association of Laryngectomee Clubs (PDF 685 KB)

Lets Face It

Lets Face It (PDF 12 KB)

Merck Serono Ltd

Merck Serono Ltd (PDF 497 KB)

Dr Nick Slevin

Head and neck cancer - cetuximab (appraisal consultation)

Head and neck cancer - cetuximab: appraisal consultation document information

Evaluation report

Response from Merck

Response from Merck (PDF 273 KB)

Non-manufacturer submissions

Joint submission from NCRI Head & Neck Clinical Studies Group, Royal College of Physicians, Royal College of Radiologists, Joint Collegiate for Oncology and Association of Cancer Physicians.

Joint submission from NCRI Head & Neck Clinical Studies Group, Royal College of Physicians, Royal College of Radiologists, Joint Collegiate for Oncology and Association of Cancer Physicians. (PDF 45 KB)

British Association of Head and Neck Oncologists

British Association of Head and Neck Oncologists (PDF 15 KB)

Letter to Merck requesting extra information following appeal decision

Letter to Merck requesting extra information following appeal decision (PDF 29 KB)

Slevin

Slevin (PDF 14 KB)

Letter to consultees and commentators requesting extra information following appeal decision

Letter to consultees and commentators requesting extra information following appeal decision (PDF 17 KB)

Appeal Decision

Appeal Decision (PDF 70 KB)

Final Appraisal Determination

Head and neck cancer - cetuximab: Final appraisal determination information

Head and neck cancer - cetuximab: Final appraisal determination

Head and neck cancer - cetuximab: Final appraisal determination (PDF 78 KB)

Response to consultee, commentator and public comments on the ACD

Response to consultee, commentator and public comments on the ACD (PDF 327 KB)

Head and neck cancer: Final appraisal determination - Nick Slevin

Head and neck cancer: Final appraisal determination - Nick Slevin (PDF 41 KB)

Expert comments on the ACD

Head and neck cancer: Final appraisal determination - Let's face it

Head and neck cancer: Final appraisal determination - Let's face it (PDF 16 KB)

Head and neck cancer: Final appraisal determination - Merck Pharmaceuticals

Head and neck cancer: Final appraisal determination - Merck Pharmaceuticals (PDF 169 KB)

Head and neck cance: Final appraisal determination - Royal College Nursing

Head and neck cance: Final appraisal determination - Royal College Nursing (PDF 22 KB)

Head and neck cancer: Final appraisal determination - Royal College of Pathologists

Head and neck cancer: Final appraisal determination - Royal College of Pathologists (PDF 43 KB)

Head and neck cancer: Final appraisal determination - British Association of Head and Neck Oncologists

Head and neck cancer: Final appraisal determination - British Association of Head and Neck Oncologists (PDF 20 KB)

Head and neck cancer: Final appraisal determination - King's College Hospital Maxilliofacial Unit - The Head and Neck Oncology Group

Evidence considered

Additional evidence considered

EPAR report

EPAR report (PDF 696 KB)

Clinical Expert Written Statement on EPAR report

Clinical Expert Written Statement on EPAR report (PDF 17 KB)

Manufacturer submission

Manufacturer submission

Manufacturer submission (PDF 835 KB)

Technical appendix 1 Economics model variables

Technical appendix 1 Economics model variables (PDF 177 KB)

Technical appendix 2

Technical appendix 2 (PDF 82 KB)

Technical appendix 3

Technical appendix 3 (PDF 491 KB)

Expert written personal statements

Brady

Brady (PDF 42 KB)

Fraser

Fraser (PDF 50 KB)

Harrington

Harrington (PDF 40 KB)

Slevin

Slevin (PDF 2.06 MB)

Pre meeting briefing

Pre meeting briefing (PDF 60 KB)

Head and neck cancer - cetuximab: evidence Review Group report

Update to Consultees and Commentators